alexa
Reach Us +1-947-333-4405
Development Of Aptamer-based HIV-1 Entry Inhibitor Prophylactic Drug | 9212
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Development of aptamer-based HIV-1 entry inhibitor prophylactic drug

2nd International Conference and Exhibition on Pathology

Grace London, Hazel Mufhandu, Devin Sok, Bongani Mayosi, Lynn Morris, Dennis Burton and Makobetsa Khati

ScientificTracks Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681.S1.008

Abstract
AIDS remains a major public health problem globally, especially in Southern Africa where over 6.4 million people are infected by the most prevalent HIV-1 subtype C. To help stop the spread of HIV-1 subtype C, we isolated 2ʹ-F-RNA aptamers against gp120, with a view of developing them as entry inhibitor drugs. In this study, we evaluated the neutralization activity of two aptamers (CSIR1.1 and UCLA1) against HIV-1 subtype C, their toxicity effects and mapped their epitopes on gp120. UCLA1 and CSIR1.1 were tested against a 32 Env pseudotyped panel from HIV-1 subtype C. In addition, UCLA1 was further tested against 10 clinical isolates in PBMC and MDM. We evaluated the cytotoxic effects of aptamers in target cells using ATP and PMTS proliferation assay and mapped their epitopes on gp120 by site directed mutagenesis. UCLA1 and CSIR1.1 neutralized infectivity of 79 % and 84 % pseudotyped viruses, respectively. UCLA1, further inhibited more than 60 % of clinical isolates. We noted that, aptamers neutralized both R5 and X4 tropic viruses with mean IC 50 value of 10 nM and did not affect cell viability after 72 hrs incubation with a concentration of 500 nM. The mapping studies revealed that CSIR1.1 and UCLA1 bind to conserved region of V1/V2 region and V3 loop on gp120. Our results showed that RNA aptamers prevent infection of HIV-1 subtype C by binding to conserved regions on gp120, without toxicity effects. This warrant further studies to develop RNA aptamer as prophylactic drugs to prevent infection of HIV-1 subtype C.
Biography
Grace, recently submitted her Ph.D. for evaluation at University of Cape Town collaboration with CSIR (Council for Scientific and Industrial Research). She completed part of her Ph.D. at Scripps Research Institute after being awarded the Fogarty global scholarship and recently won a clinical excellence awards at the 6 th South African AIDS conference.
Top